Last reviewed · How we verify
dulaglutide injection
Dulaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and reduce glucagon release in response to elevated blood glucose.
Dulaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and reduce glucagon release in response to elevated blood glucose. Used for Type 2 diabetes mellitus, Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease.
At a glance
| Generic name | dulaglutide injection |
|---|---|
| Also known as | diet and exercise guidance treatment, Trulicity, TRULICITY®, Other hypoglycemic agents not including GLP-1 receptor agonists |
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Dulaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also slows gastric emptying and promotes satiety, leading to reduced food intake and improved glycemic control. Additionally, it has cardiovascular benefits including blood pressure reduction and weight loss.
Approved indications
- Type 2 diabetes mellitus
- Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Hypoglycemia
- Injection site reactions
Key clinical trials
- Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia (PHASE2)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes (PHASE2)
- A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin (PHASE3)
- A Phase 3 Study of HS-20094 in Patients With T2DM (PHASE3)
- GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery (PHASE4)
- A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus (PHASE3)
- A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dulaglutide injection CI brief — competitive landscape report
- dulaglutide injection updates RSS · CI watch RSS
- First Affiliated Hospital of Zhejiang University portfolio CI